NANO MRNA Co.,Ltd.
Tokyo Stock ExchangeTotal Valuation
NANO MRNA Co.,Ltd. carries a market capitalization of 8.49B, placing it among publicly traded companies globally. Its enterprise value stands at 9.82B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 8.49B |
| Enterprise Value | 9.82B |
Share Statistics
NANO MRNA Co.,Ltd. currently has 70.60M shares outstanding.
| Shares Outstanding | 70.60M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 288.19, and the price-to-book ratio stands at -5.11.
| PE Ratio | N/A |
| PS Ratio | 288.19 |
| PB Ratio | -5.11 |
| P/TBV Ratio | 4.19 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 221.19 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
NANO MRNA Co.,Ltd. maintains a current ratio of 8.17, meaning it holds 8.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 8.17 |
| Quick Ratio | 7.86 |
| Debt / Equity | 36.27 |
| Debt / EBITDA | -3.21 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -5.95 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 6.02 |
Taxes
| Income Tax | -730,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
NANO MRNA Co.,Ltd.'s stock has declined approximately -23.30827% over the past 52 weeks. The 50-day moving average sits at 118.08, while the 200-day moving average is 144.19.
| Beta (5Y) | N/A |
| 52-Week Price Change | -23.30827% |
| 50-Day Moving Average | 118.08 |
| 200-Day Moving Average | 144.19 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, NANO MRNA Co.,Ltd. generated 44.40M in revenue and converted that into -302.64M in net income, yielding earnings per share of -4.30. EBITDA reached -345.79M, while operating income came in at -345.79M.
| Revenue | 44.40M |
| Gross Profit | 35.76M |
| Operating Income | -345.79M |
| Pretax Income | -303.37M |
| Net Income | -302.64M |
| EBITDA | -345.79M |
| EBIT | -345.79M |
| Earnings Per Share (EPS) | -4.30 |
Balance Sheet
NANO MRNA Co.,Ltd. holds 4.08B in cash and equivalents against 1.11B in total debt, resulting in a net debt position of -1.77B. Total book value stands at -2.50B, with working capital of 3.72B providing operational flexibility.
| Cash & Cash Equivalents | 4.08B |
| Total Debt | 1.11B |
| Net Debt | -1.77B |
| Equity (Book Value) | -2.50B |
| Book Value Per Share | -35.61 |
| Working Capital | 3.72B |
Margins
NANO MRNA Co.,Ltd. operates with a gross margin of 80.55, reflecting its pricing power and cost economics. The operating margin of -778.81 and net profit margin of -681.63 provide insight into operational efficiency.
| Gross Margin | 80.55 |
| Operating Margin | -778.81 |
| Pretax Margin | -683.27 |
| Profit Margin | -681.63 |
| EBITDA Margin | -778.81 |
Stock Splits
NANO MRNA Co.,Ltd.'s most recent stock split took place on March 27, 2014 with a 1:100 split ratio.
| Last Split Date | 3/27/2014 |
| Split Ratio | 1:100 |
Scores
NANO MRNA Co.,Ltd. posts an Altman Z-Score of 4.49, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.49 |